BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Overton ET, Kitch D, Benson CA, Hunt PW, Stein JH, Smurzynski M, Ribaudo HJ, Tebas P. Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death. Clin Infect Dis 2013;56:1471-9. [PMID: 23386631 DOI: 10.1093/cid/cit053] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Cutrell J, Bedimo R. Non-AIDS-defining cancers among HIV-infected patients. Curr HIV/AIDS Rep 2013;10:207-16. [PMID: 23743643 DOI: 10.1007/s11904-013-0166-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
2 Mosepele M, Molefe-Baikai OJ, Grinspoon SK, Triant VA. Benefits and Risks of Statin Therapy in the HIV-Infected Population. Curr Infect Dis Rep 2018;20:20. [PMID: 29804227 DOI: 10.1007/s11908-018-0628-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
3 Nou E, Lo J, Hadigan C, Grinspoon SK. Pathophysiology and management of cardiovascular disease in patients with HIV. Lancet Diabetes Endocrinol 2016;4:598-610. [PMID: 26873066 DOI: 10.1016/S2213-8587(15)00388-5] [Cited by in Crossref: 45] [Cited by in F6Publishing: 26] [Article Influence: 7.5] [Reference Citation Analysis]
4 Borges ÁH. Combination antiretroviral therapy and cancer risk. Curr Opin HIV AIDS 2017;12:12-9. [PMID: 27755153 DOI: 10.1097/COH.0000000000000334] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 4.2] [Reference Citation Analysis]
5 Hsu DC, Sereti I, Ananworanich J. Serious Non-AIDS events: Immunopathogenesis and interventional strategies. AIDS Res Ther 2013;10:29. [PMID: 24330529 DOI: 10.1186/1742-6405-10-29] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 4.7] [Reference Citation Analysis]
6 Uthman OA, Nduka C, Watson SI, Mills EJ, Kengne AP, Jaffar SS, Clarke A, Moradi T, Ekström AM, Lilford R. Statin use and all-cause mortality in people living with HIV: a systematic review and meta-analysis. BMC Infect Dis 2018;18:258. [PMID: 29866059 DOI: 10.1186/s12879-018-3162-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
7 Jacobson TA, Maki KC, Orringer CE, Jones PH, Kris-etherton P, Sikand G, La Forge R, Daniels SR, Wilson DP, Morris PB, Wild RA, Grundy SM, Daviglus M, Ferdinand KC, Vijayaraghavan K, Deedwania PC, Aberg JA, Liao KP, Mckenney JM, Ross JL, Braun LT, Ito MK, Bays HE, Brown WV. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. Journal of Clinical Lipidology 2015;9:S1-S122.e1. [DOI: 10.1016/j.jacl.2015.09.002] [Cited by in Crossref: 243] [Cited by in F6Publishing: 196] [Article Influence: 34.7] [Reference Citation Analysis]
8 Vizcarra P, Guillemi S, Eyawo O, Hogg RS, Montaner JS, Bennett M. Stroke and Systemic Thromboembolism Prevention in People Living With Human Immunodeficiency Virus With Atrial Fibrillation: A Review of Its Implications for Clinical Practice. CJC Open 2019;1:245-55. [PMID: 32159116 DOI: 10.1016/j.cjco.2019.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Erlandson KM, Jiang Y, Debanne SM, McComsey GA. Effects of randomized rosuvastatin compared with placebo on bone and body composition among HIV-infected adults. AIDS 2015;29:175-82. [PMID: 25396266 DOI: 10.1097/QAD.0000000000000526] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
10 Bratt G, Brännström J, Missalidis C, Nyström T. Development of type 2 diabetes and insulin resistance in people with HIV infection: Prevalence, incidence and associated factors. PLoS One 2021;16:e0254079. [PMID: 34191847 DOI: 10.1371/journal.pone.0254079] [Reference Citation Analysis]
11 Bedimo RJ, Park LS, Shebl FM, Sigel K, Rentsch CT, Crothers K, Rodriguez-Barradas MC, Goetz MB, Butt AA, Brown ST, Gibert C, Justice AC, Tate JP. Statin exposure and risk of cancer in people with and without HIV infection. AIDS 2021;35:325-34. [PMID: 33181533 DOI: 10.1097/QAD.0000000000002748] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Drechsler H, Ayers C, Cutrell J, Maalouf N, Tebas P, Bedimo R. Current use of statins reduces risk of HIV rebound on suppressive HAART. PLoS One 2017;12:e0172175. [PMID: 28249009 DOI: 10.1371/journal.pone.0172175] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
13 Hunt PW. HIV and aging: emerging research issues. Curr Opin HIV AIDS 2014;9:302-8. [PMID: 24824891 DOI: 10.1097/COH.0000000000000072] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 4.7] [Reference Citation Analysis]
14 Spagnuolo V, Galli L, Poli A, Salpietro S, Gianotti N, Piatti P, Cossarini F, Vinci C, Carini E, Lazzarin A, Castagna A. Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients. BMC Infect Dis 2017;17:43. [PMID: 28061820 DOI: 10.1186/s12879-016-2099-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
15 Galli L, Spagnuolo V, Poli A, Salpietro S, Gianotti N, Cossarini F, Carbone A, Nozza S, Bossolasco S, Bigoloni A, Lazzarin A, Castagna A. Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy. AIDS 2014;28:2407-15. [PMID: 25160933 DOI: 10.1097/QAD.0000000000000443] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
16 Waters DD, Hsue PY. Lipid Abnormalities in Persons Living With HIV Infection. Can J Cardiol 2019;35:249-59. [PMID: 30704819 DOI: 10.1016/j.cjca.2018.11.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
17 Warriner AH, Burkholder GA, Overton ET. HIV-related metabolic comorbidities in the current ART era. Infect Dis Clin North Am 2014;28:457-76. [PMID: 25151566 DOI: 10.1016/j.idc.2014.05.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
18 McGettrick P, Barco EA, Mallon PWG. Ageing with HIV. Healthcare (Basel) 2018;6:E17. [PMID: 29443936 DOI: 10.3390/healthcare6010017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
19 Bedimo R, Abodunde O. Metabolic and Cardiovascular Complications in HIV/HCV-Co-infected Patients. Curr HIV/AIDS Rep. 2016;13:328-339. [PMID: 27595755 DOI: 10.1007/s11904-016-0333-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
20 Gobert A, Mounier N, Lavole A, Poizot-Martin I, Spano JP. [HIV-related malignancies: state of art]. Bull Cancer 2014;101:1020-9. [PMID: 25418594 DOI: 10.1684/bdc.2014.2032] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
21 Titanji B, Gavegnano C, Hsue P, Schinazi R, Marconi VC. Targeting Inflammation to Reduce Atherosclerotic Cardiovascular Risk in People With HIV Infection. J Am Heart Assoc 2020;9:e014873. [PMID: 31973607 DOI: 10.1161/JAHA.119.014873] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
22 Escota GV, O'Halloran JA, Powderly WG, Presti RM. Understanding mechanisms to promote successful aging in persons living with HIV. Int J Infect Dis 2018;66:56-64. [PMID: 29154830 DOI: 10.1016/j.ijid.2017.11.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
23 Eckard AR, McComsey GA. The role of statins in the setting of HIV infection. Curr HIV/AIDS Rep 2015;12:305-12. [PMID: 26126687 DOI: 10.1007/s11904-015-0273-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
24 Krsak M, Kent DM, Terrin N, Holcroft C, Skinner SC, Wanke C. Myocardial Infarction, Stroke, and Mortality in cART-Treated HIV Patients on Statins. AIDS Patient Care STDS 2015;29:307-13. [PMID: 25855882 DOI: 10.1089/apc.2014.0309] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
25 Lang S, Lacombe JM, Mary-Krause M, Partisani M, Bidegain F, Cotte L, Aslangul E, Chéret A, Boccara F, Meynard JL, Pradier C, Roger PM, Tattevin P, Costagliola D, Molina JM; French Hospital Database on HIV. Is Impact of Statin Therapy on All-Cause Mortality Different in HIV-Infected Individuals Compared to General Population? Results from the FHDH-ANRS CO4 Cohort. PLoS One 2015;10:e0133358. [PMID: 26200661 DOI: 10.1371/journal.pone.0133358] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
26 Vigouroux C, Bastard J, Capeau J. Emerging clinical issues related to management of multiorgan comorbidities and polypharmacy: . Current Opinion in HIV and AIDS 2014;9:371-8. [DOI: 10.1097/coh.0000000000000068] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
27 Blonk M, van Beek M, Colbers A, Schouwenberg B, Burger D. Pharmacokinetic Drug–Drug Interaction Study Between Raltegravir and Atorvastatin 20 mg in Healthy Volunteers. JAIDS Journal of Acquired Immune Deficiency Syndromes 2015;69:44-51. [DOI: 10.1097/qai.0000000000000544] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
28 Abdo M, Langan SJ, MaWhinney S, Sun J, Lake JE, Palella FJ, Kingsley L, Brown TT, Erlandson KM. Effect of Statin Therapy on Age-Associated Changes in Physical Function Among Men With and Without HIV in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 2021;86:455-62. [PMID: 33230030 DOI: 10.1097/QAI.0000000000002579] [Reference Citation Analysis]
29 Li Y, Wang Z, Xia H, Zhang J. Influence of Statin Therapy on the Incidence of Cardiovascular Events, Cancer, and All-Cause Mortality in People Living With HIV: A Meta-Analysis. Front Med (Lausanne) 2021;8:769740. [PMID: 34820402 DOI: 10.3389/fmed.2021.769740] [Reference Citation Analysis]
30 d'Ettorre G, Ceccarelli G, Pavone P, Vittozzi P, De Girolamo G, Schietroma I, Serafino S, Giustini N, Vullo V. What happens to cardiovascular system behind the undetectable level of HIV viremia? AIDS Res Ther 2016;13:21. [PMID: 27127532 DOI: 10.1186/s12981-016-0105-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
31 Erlandson KM, Jiang Y, Debanne SM, McComsey GA. Rosuvastatin Worsens Insulin Resistance in HIV-Infected Adults on Antiretroviral Therapy. Clin Infect Dis 2015;61:1566-72. [PMID: 26157049 DOI: 10.1093/cid/civ554] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
32 Metkus TS Jr, Brown TT, Post WS. Cardiovascular disease associated with the human immunodeficiency virus: an update. Curr Treat Options Cardiovasc Med 2014;16:346. [PMID: 25193559 DOI: 10.1007/s11936-014-0346-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
33 Longenecker CT, Eckard AR, McComsey GA. Statins to improve cardiovascular outcomes in treated HIV infection. Curr Opin Infect Dis 2016;29:1-9. [PMID: 26658651 DOI: 10.1097/QCO.0000000000000223] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
34 Drechsler H, Ayers C, Cutrell J, Arasaratnam R, Bedimo R. Consistent use of lipid lowering therapy in HIV infection is associated with low mortality. BMC Infect Dis 2021;21:150. [PMID: 33546621 DOI: 10.1186/s12879-021-05787-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Silverberg MJ, Lau B, Achenbach CJ, Jing Y, Althoff KN, D'Souza G, Engels EA, Hessol NA, Brooks JT, Burchell AN, Gill MJ, Goedert JJ, Hogg R, Horberg MA, Kirk GD, Kitahata MM, Korthuis PT, Mathews WC, Mayor A, Modur SP, Napravnik S, Novak RM, Patel P, Rachlis AR, Sterling TR, Willig JH, Justice AC, Moore RD, Dubrow R; North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS. Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study. Ann Intern Med 2015;163:507-18. [PMID: 26436616 DOI: 10.7326/M14-2768] [Cited by in Crossref: 183] [Cited by in F6Publishing: 100] [Article Influence: 30.5] [Reference Citation Analysis]
36 Calcagno A, Nozza S, Muss C, Celesia BM, Carli F, Piconi S, De Socio GV, Cattelan AM, Orofino G, Ripamonti D, Riva A, Di Perri G. Ageing with HIV: a multidisciplinary review. Infection 2015;43:509-22. [PMID: 25987480 DOI: 10.1007/s15010-015-0795-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
37 Saez-Cirion A, Jacquelin B, Barré-Sinoussi F, Müller-Trutwin M. Immune responses during spontaneous control of HIV and AIDS: what is the hope for a cure? Philos Trans R Soc Lond B Biol Sci 2014;369:20130436. [PMID: 24821922 DOI: 10.1098/rstb.2013.0436] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
38 Rubinstein PG, Aboulafia DM, Zloza A. Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges. AIDS 2014;28:453-65. [PMID: 24401642 DOI: 10.1097/QAD.0000000000000071] [Cited by in Crossref: 140] [Cited by in F6Publishing: 62] [Article Influence: 17.5] [Reference Citation Analysis]
39 Wang SC, Kaur G, Schulman-Marcus J, Purga S, Mookherjee S, Miller C, Sidhu MS, Rosenson RS. Implementation of Cholesterol-Lowering Therapy to Reduce Cardiovascular Risk in Persons Living with HIV. Cardiovasc Drugs Ther 2020. [PMID: 32979175 DOI: 10.1007/s10557-020-07085-8] [Reference Citation Analysis]
40 Borges AH, Dubrow R, Silverberg MJ. Factors contributing to risk for cancer among HIV-infected individuals, and evidence that earlier combination antiretroviral therapy will alter this risk. Curr Opin HIV AIDS 2014;9:34-40. [PMID: 24225382 DOI: 10.1097/COH.0000000000000025] [Cited by in Crossref: 46] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
41 McComsey GA, Kitch D, Sax PE, Tierney C, Jahed NC, Melbourne K, Ha B, Brown TT, Bloom A, Fedarko N, Daar ES. Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202. J Acquir Immune Defic Syndr 2014;65:167-74. [PMID: 24121755 DOI: 10.1097/01.qai.0000437171.00504.41] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 6.0] [Reference Citation Analysis]
42 Negredo E, Jiménez M, Puig J, Loste C, Pérez-Álvarez N, Urrea V, Echeverría P, Bonjoch A, Clotet B, Blanco J. A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV. PLoS One 2020;15:e0238575. [PMID: 32941476 DOI: 10.1371/journal.pone.0238575] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 Pereira B, Mazzitelli M, Milinkovic A, Moyle G, Ranasinghe S, Mandalia S, Pozniak A, Asboe D, Nelson M, Al-Hussaini A, Boffito M. Use of Coronary Artery Calcium Scoring to Improve Cardiovascular Risk Stratification and Guide Decisions to Start Statin Therapy in People Living With HIV. J Acquir Immune Defic Syndr 2020;85:98-105. [PMID: 32398558 DOI: 10.1097/QAI.0000000000002400] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
44 Pyarali F, Iordanov R, Ebner B, Grant J, Vincent L, Toirac A, Haque T, Zablah G, Kapoor K, Powell A, Boulanger C, Hurwitz B, Alcaide M, Martinez C. Cardiovascular disease and prevention among people living with HIV in South Florida. Medicine (Baltimore) 2021;100:e26631. [PMID: 34260554 DOI: 10.1097/MD.0000000000026631] [Reference Citation Analysis]
45 Levy ME, Greenberg AE, Magnus M, Younes N, Castel A. Evaluation of Statin Eligibility, Prescribing Practices, and Therapeutic Responses Using ATP III, ACC/AHA, and NLA Dyslipidemia Treatment Guidelines in a Large Urban Cohort of HIV-Infected Outpatients. AIDS Patient Care STDS 2018;32:58-69. [PMID: 29561173 DOI: 10.1089/apc.2017.0304] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
46 Schnitzer ME, Lok JJ, Bosch RJ. Double robust and efficient estimation of a prognostic model for events in the presence of dependent censoring. Biostatistics 2016;17:165-77. [PMID: 26224070 DOI: 10.1093/biostatistics/kxv028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
47 Overton ET, Sterrett S, Westfall AO, Kahan SM, Burkholder G, Zajac AJ, Goepfert PA, Bansal A. Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patients. AIDS 2014;28:2627-31. [PMID: 25574964 DOI: 10.1097/QAD.0000000000000475] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
48 Elahi S, Weiss RH, Merani S. Atorvastatin restricts HIV replication in CD4+ T cells by upregulation of p21. AIDS 2016;30:171-83. [PMID: 26645604 DOI: 10.1097/QAD.0000000000000917] [Cited by in Crossref: 37] [Cited by in F6Publishing: 24] [Article Influence: 6.2] [Reference Citation Analysis]